BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/4/2014 2:00:00 PM | Browse: 1643 | Download: 1492
Publication Name World Journal of Gastrointestinal Oncology
Manuscript ID 1459
Country Spain
ISSN 1948-5204 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Topic Highlights
Article Title Chemotherapy for cholangiocarcinoma: An update
Manuscript Source Invited Manuscript
All Author List Natalia Ramírez-Merino, Santiago Ponce Aix and Hernán Cortés-Funes
Funding Agency and Grant Number
Corresponding Author Dr. Natalia Ramírez-Merino, Department of Medical Oncology, Clinica La Luz, C/ General Rodrigo 8, 28003 Madrid, Spain. narame2@gmail.com
Key Words Chemotherapy; Cholangiocarcinoma; Review; Oncology; Gemcitabine
Core Tip Cholangiocarcinomas (bile duct cancers) are an heterogeneous group of malignancies arising from the epithelial cells of the intrahepatic, perihilar and extrahepatic bile ducts. Leucovorin-modulated 5-fluorouracil, capecitabine monotherapy or single agent gemcitabine are reasonable options for patients with a borderline performance status. After progression in patients with an adequate performance status, active regimens that could be considered for second line treatment include gemcitabine plus capecitabine or erlotinib plus bevacizumab.
Publish Date 2013-07-31 09:53
Citation Ramírez-Merino N, Aix SP, Cortés-Funes H. Chemotherapy for cholangio- carcinoma: An update. World J Gastrointest Oncol 2013; 5(7): 171-176
URL http://www.wjgnet.com/1948-5204/full/v5/i7/171.htm
DOI http://dx.doi.org/10.4251/wjgo.v5.i7.171
Full Article (PDF) WJGO-5-171.pdf